Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

BACKGROUND: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jouneau, Stéphane, Crestani, Bruno, Thibault, Ronan, Lederlin, Mathieu, Vernhet, Laurent, Valenzuela, Claudia, Wijsenbeek, Marlies, Kreuter, Michael, Stansen, Wibke, Quaresma, Manuel, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690188/
https://www.ncbi.nlm.nih.gov/pubmed/33239000
http://dx.doi.org/10.1186/s12931-020-01528-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690188/
https://www.ncbi.nlm.nih.gov/pubmed/33239000
http://dx.doi.org/10.1186/s12931-020-01528-4

Ejemplares similares